Provided are an L-proline complex of a sodium-glucose cotransporter 2 inhibitor, and a monohydrate and a crystal of the L-proline complex. Specifically, provided are 1,6-dehydrated-1—C{4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl}-5—C-(hydroxymethyl)-β-L-idopyranose L-proline (a compound of formula (I)), a monohydrate and a type A crystal thereof, and a preparation method therefor. The obtained type A crystal of the compound of formula (I) has good chemical stability and crystal stability, and the crystallization solvent used has low toxicity and low residue, so the type A crystal can be better used in clinical treatment.

##STR00001##

Provided are an L-proline complex of a sodium-glucose cotransporter 2 inhibitor, and a monohydrate and a crystal of the L-proline complex. Specifically, provided are 1,6-dehydrated-1—C{4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl}-5—C-(hydroxymethyl)-β-L-idopyranose L-proline (a compound of formula (I)), a monohydrate and a type A crystal thereof, and a preparation method therefor. The obtained type A crystal of the compound of formula (I) has good chemical stability and crystal stability, and the crystallization solvent used has low toxicity and low residue, so the type A crystal can be better used in clinical treatment.

##STR00001##

The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.

The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.

The present invention provides a method of preparing a furan derivative comprising the steps of (a) converting a monosaccharide to provide a keto-intermediate product; and (b) dehydrating the keto-intermediate product to provide a furan derivative; wherein the keto-intermediate product is pre-disposed to forming keto-furanose tautomers in solution. The method may further comprising a step of oxidizing the furan derivative to provide a furandicarboxylic acid or a furandicarboxylic acid derivative.

The present invention provides a method of preparing a furan derivative comprising the steps of (a) converting a monosaccharide to provide a keto-intermediate product; and (b) dehydrating the keto-intermediate product to provide a furan derivative; wherein the keto-intermediate product is pre-disposed to forming keto-furanose tautomers in solution. The method may further comprising a step of oxidizing the furan derivative to provide a furandicarboxylic acid or a furandicarboxylic acid derivative.

Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions comprising the 13-membered macrolides, and methods of treating infectious diseases, and in particular, disease resulting from Gram negative bacteria using the disclosed macrolides.

Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions comprising the 13-membered macrolides, and methods of treating infectious diseases, and in particular, disease resulting from Gram negative bacteria using the disclosed macrolides.

The Notice states that an abstract of the technical disclosure is required. In response, Applicant submits herewith a Preliminary Amendment including an abstract in compliance with 37 CFR § 1.72(b). The abstract is based on that submitted in parent U.S. application Ser. No. 15/556,084 (issued as U.S. Pat. No. 11,193,106) and international application no. PCT/US2016/020621, of which U.S. application Ser. No. 15/556,084 is the US national stage application. The submitted abstract differs from the abstract of the parent application only by a correction of “may further comprising” to “may further comprise”. Thus, the abstract contains no new matter.

The Notice states that an abstract of the technical disclosure is required. In response, Applicant submits herewith a Preliminary Amendment including an abstract in compliance with 37 CFR § 1.72(b). The abstract is based on that submitted in parent U.S. application Ser. No. 15/556,084 (issued as U.S. Pat. No. 11,193,106) and international application no. PCT/US2016/020621, of which U.S. application Ser. No. 15/556,084 is the US national stage application. The submitted abstract differs from the abstract of the parent application only by a correction of “may further comprising” to “may further comprise”. Thus, the abstract contains no new matter.